185750 — Chong Kun Dang Pharmaceutical Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩2tn
- KR₩1tn
- KR₩2tn
- 94
- 67
- 73
- 95
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 92,373 | 161,855 | 187,333 | 155,861 | 364,253 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 198,007 | 219,514 | 228,295 | 279,749 | 310,140 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 471,135 | 600,114 | 667,147 | 713,615 | 946,572 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 263,086 | 274,650 | 298,910 | 310,697 | 319,787 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 801,352 | 946,333 | 1,046,700 | 1,124,883 | 1,402,428 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 277,069 | 320,621 | 320,230 | 374,213 | 511,466 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 327,832 | 394,906 | 480,690 | 502,490 | 586,734 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 473,520 | 551,427 | 566,010 | 622,393 | 815,694 |
Total Liabilities & Shareholders' Equity | 801,352 | 946,333 | 1,046,700 | 1,124,883 | 1,402,428 |
Total Common Shares Outstanding |